Dynamic evolution of ponatinib‐resistant mutations in BCR–ABL1 ‐positive leukaemias revealed by next‐generation sequencing-Reference-Cited by-同舟云学术

Dynamic evolution of ponatinib‐resistant mutations in BCR–ABL1 ‐positive leukaemias revealed by next‐generation sequencing

Published:2020-09-10 Issue:5 Volume:191 Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br. J. Haematol.

Author:

Chen Jiaqi¹²^ORCID,Wang Fang¹,Fang Jiancheng¹,Nie Daijing¹^ORCID,Zhang Yang¹,Chen Xue¹^ORCID,Li Yu³,Tan Yincheng¹,Ma Xiaoli¹,Guo Yongxin¹,Cao Panxiang¹,Liu Ming¹,Liu Hongxing¹²³^ORCID

Affiliation:

1. Division of Pathology & Laboratory Medicine Hebei Yanda Lu Daopei Hospital Langfang China

2. Beijing Lu Daopei Institute of Hematology Beijing China

3. Division of Pathology & Laboratory Medicine Beijing Lu Daopei Hospital Beijing China

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17068

Reference12 articles.

1. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

2. BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib

3. Novel TKI-resistant BCR-ABL1 gatekeeper residue mutations retain in vitro sensitivity to axitinib

4. BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia

5. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Celastrol induces DNA damage and cell death in BCR-ABL T315I-mutant CML by targeting YY1 and HMCES;Phytomedicine;2024-11

2. Characteristics and literature review of ETV6::ABL1 fusion gene-positive acute myeloid leukemia;International Journal of Hematology;2024-03-05

3. Exploiting the potential of the ubiquitin-proteasome system in overcoming tyrosine kinase inhibitor resistance in chronic myeloid leukemia;Genes & Diseases;2023-10

4. Mechanism of Procyanidin B2 in the Treatment of Chronic Myeloid Leukemia Based on Integrating Network Pharmacology and Molecular Docking;Anti-Cancer Agents in Medicinal Chemistry;2023-10

5. Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?;Expert Review of Anticancer Therapy;2022-11-24